is into steam investments at year. and ] same to toward result made all made strategic ClearPoint of will year, we along goals that have as potential and of which well the as partnership is start and XXXX Thanks, This to as beyond. have [ the significant start gain the will opportunity portfolio, company goals in Danilo. benefit the XXXX team number a off product great to multiple a this operating a grow different investors time. we the have progress both financial for This to we the of
navigation PRISM and Laser into system partners and they our MRI-guided and beyond five, the complementing rate. These preclinical Therapy adding XXXX trial and OR room, system, expanding new XX% increasing hospitals our Number number Number two, more in research three, customers. move of with opportunities take growth SmartFrame same-store accelerated delivery participating existing to all adding biotech clinical as biologics benchtop and at operating first-in-human trials. our include: new progression our place. offering our number with portfolio, and the where sales preclinical the installed to into clinical than four, of our and centers the an one, procedures base Number services drug
we contribute of XXXX. growth double-digit the to all segments result, expect to our a As meaningful in company
$XX X the We revenue Thus again, breaks million, our that to of continue into for started with and expect in as we year $XX mentioned, already down growth of in strong million progress the to growth the range XX% QX. year here pillars.
business, XX% biologics largest in first and drug segment, the our our First, which quarter. perform and delivery is grew continued to
with system of of well predictable and Our continue monitoring infusion studied technology imaging the software and to comprehensive Maestro cannulas SmartFlow confidence documentation cannulas the therapy with infusions be and targeting to and core leading the for procedure with live MRI, cell using due our precision our of ClearPoint Navigation the gene and our AI-derived success guidance and software.
only is and add-ons solution believe to to our comprehensive further none extend refinements second and will position. continue We leading our
the one is gene submission therapy in ever saw PTC deficiency therapy partners, Importantly, here commercial [ AADC This gene submission reflects data and potentially XXXX. the to in for BLA drug first sometime first QX, our important milestone their we could by neuro United lead and of a in of Therapeutics product ]. an the States
another frontal patient their another temporal We also dosing severely lobe partner treatment for disease. Yota of their ] ever Bio dementia, congratulated which first a of debilitating experimental [ human with for is
to balance II We continue and bench year, the Phase into and drugs expect updates Phase additional trial. these programs preclinical this these the the as during multiple graduate of first-in-human crucial from phased progress partners of testing I of to leading progression
and milestones, come their includes royalties. We commercial with drug of modeling added partnerships fully to agreements prototyping our pharma, assurances clinical will for drug-based to biologics that predictive us also capabilities providing that team, Due strategy product by as pharma, are XX% and already to strategic are programs routes other device supply may to combination co-development and to supply. be This derisk additional their These of pricing pursue portfolio showing allow which happy and therapy partners part new results administration we AI-derived actual as long-term for software. or additions of to include programs, our testing and we growth years of with essential the monitoring more preclinical recognize commitments co-labeling an well have rate. chain our which
which predicting will is our achieved. when The be most be model part challenging successful of will and commercialization business partners
these done has Our into opportunities. team turning job challenges an amazing
across reduced partners. First, by both we the risk indications have goal success and on multiple across having shots
We more we states, are significant a it on our impact currently even the than are active XX different revenue. have diseases meaning be redundancy multiple do current X have the in to if often encounter X indication. could meaning a of few partner just we successful solved, every not per have Similarly, or created indications, only within we treat looking same to these and disease partners need disease
risk diseases, also In both this to having of biotechnology downside. do clinical bear be neuro fund we expensive across our attractive the companies, diversified of where not as an ETF trials capital may viewed are sense, we and we these partners but limiting
$XXX create adding risk each breakeven products gene believe of the a or With million XX to portfolio, order the to these our services capabilities would commercialization with partner ClearPoint and of and reduced every has for our ever opportunity positive this Realizing into revenue over to to have than preclinical stage the approved timing would of the these drug and we generate could to up the cell an by the more years a having of commercialized. opportunity to of partners. us cash fund drugs. without company existing existing to close commercialization Second, achieve one group equate $XX million opportunity on all be also new-to-world that allow enough flow That a before of our rely cash and therapies. and services to and current next we
counterpart on represent month meeting, again European sales and and Meeting significant our meetings process often Cell Society a Therapy of are immediate These in heels show to participating we and of Italy. American week, place the this in an is in Gene which Just of last company. pharma part Baltimore, took Rome, return the BXB which the Annual biotech
It our and to appears market raised market. be reassuring we seeing pickup that at seem both capital Bottom into in putting the is and companies in that the into be partners the successfully to the time. a seem place have biotech investment rebound be this ] the the many mid-cap is especially of capital time device to small pose we [ significant at again space, right biotech right at and same line and
#X Moving or navigation. Pillar functional on neurosurgery to
few Here, very we on fronts. made important have progress a
First, we revenue, capital new which demand a for saw highest traditional $X.X approximately to our system, MRI-guided the in leading customers opening record. and of million X was new our ever
in the you just case, capability putting an use any becoming access This unique the first ] new To we having the perspective, navigation. for year, ClearPoint modern patient every is realization put demand and that products [ year, a we in accelerated X not Even have added already ClearPoint quarter for this do offer we alone. customers the to X in essential neurosurgery XXXX, neuro for and shows department. added for if this our entire customers
every we the XXXX healthy X in funnel and in at continue have not do this do quarter keep year expect double million historic have to customers, new to adding expect we rate. $X.X a around to While revenue,
releases Brain software be Next, deep the will of ablation delivery, for planning brain and navigation our optional we key This supporting the feature saw future and release our software laser a Model stimulation Maestro prediction. capability. X.X drug that includes
SmartFrame of already into product, Finally, designed and our clearance or we the the reorder operating MRI either have ClearPoint and move announced solution which room. early all just clinical fund. our is FDA We additional cases the early week, cases great to schedule customers of suite achieved OR last first a of had out
likely meaningful ClearPoint this our limited existing and a fastest launch from does SmartFrame OR of into can components to not to the out in often require market an As reminder, any will market the play the with allow or product move year. hardware equipment. can This in to with hospital be software and full here quarter and release date half of release expect traction we third revenue second capital
the razor follow coming positive very expansion as in in placement the a is the allow to of customer blade will All base all, sales early this quarters. our the of indicator razor
and terrific pillar, well. made third we our some access in progress products, as For this therapy
belief including PRISM first continues First, limited market users progress capital with new Laser multiple Therapy and our quarter, in our very the to sale. the installations new with
Just This customer who talk a and shippers base adding added we provide This at when who to a then like them. does was a technology we using already and clarification, Prism new our product to ClearPoint that not to expand customer. customers would took PRISM. using would a base, all new that customer about as some installed count example include not customer means ClearPoint are not our new
place market and Second, today with enable laser to Laser laser procedures robotic for the the This ClearPoint are PRISM will we systems other significantly only suite, to in navigation accessible with accessory MRI the also fibers clearance the navigation that just an systems. with Navigation majority vast the FDA announced operating available PRISM of expands placed be done important Prism Fibers not than ClearPoint. in as commonly room ablation but
to We their will successful provide believe solution laser these benefits into focus and a the fits workflow in as we of generation existing can option. to ClearPoint PRISM But converting navigation. on laser customers step some therapy now we many X, be that of earlier
see revenue you an If XX% segment that you navigation prior laser showed will decline QX for disposables, our year. look at and versus the
brain you actual service was if our flat. much pretty product revenue, computer revenue However, remove interface the
navigation positive customers, growth expect revenue, in Given for the the second segment new addition double-digit therapy we the to room new return here of to quarter. starting operating new and
of significant progress achieving And scale, finally, well. X as global have number pillar we made
Our on international on new our We to is grow, which installations geographies ClearPoint, crucial and of solidify drug to nature set delivery we behalf our many further pharma to global continue to forward new approvals work continue to submissions the regulatory partners. regulatory of for look countries for of adding strategies.
with earnings progress the cash margin first In the turn last keeping while The and As us we call, repay you we than in quarter. growing show XXXX. which solidified a potentially breakeven yielded execution we limited targeted in want operational expenses March just solid the million, which proceeds operating to revenue million convertible cash XX% only debt, revenue and in our cash reduced XX% for a $XX keeping flat. while net outstanding mentioned $XX balance raise on of and by our of capital OpEx towards quarter, grew operational sheet burn dollars successful to over our flat, putting see if in more in necessary, position can of by relatively equivalent by January
open With to would I that, to the questions. call any like
